A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.
about
Simultaneous analysis of quality of life and survival data.Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.Cancer clinical outcomes for minority ethnic groups.Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials.Directions for a psychology research agenda in cancer.Progression-free survival as a surrogate endpoint in advanced breast cancerQ-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.Are methods for estimating QALYs in cost-effectiveness analyses improving?Quality of life in cancer: definition, purpose, and method of measurement.Quality of life assessment in clinical cancer research.Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.Assessment of quality of life during intensive chemotherapy or bone marrow transplantation.Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
P2860
Q30683556-DD217D6B-0E97-48F1-A3D3-51ED43531469Q34085163-244C27DD-371A-472B-9FFC-953AC419F51EQ35034768-93A1B80A-3E53-41E0-844B-76FFC9FE1BA2Q35949737-E644BA57-070F-43BD-85F5-221FA5DA0AA5Q36291551-6C73A106-CE6E-4BE8-86CA-7DA9BAA85373Q36292207-1A4CBCDE-0F39-4F83-B8BA-F0F90B27190DQ36294836-909BBBBC-43D8-4511-9142-64A2ACC784C6Q36552307-AE6E9DB2-A484-4CF3-913E-03F061A68EC1Q36859184-46DA0631-6D5A-4CDB-9548-E2BA56BA3C38Q40880162-1BAFBC8A-3C6C-4E91-A61B-E42F6E499E1FQ40903176-83614425-3529-4A01-99AD-15977AAE682CQ42590178-B8539506-E1DD-4ED4-BCDD-548687D340A7Q48666084-525D6CD7-4072-4751-8795-2ED2924D97A5Q53553683-355CA4C0-3BE4-48BC-8814-0DEC5794E2C7Q53558519-D4DAFBE1-3935-4409-BFCA-8F9303C80C6E
P2860
A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh-hant
name
A new endpoint for the assessm ...... n with operable breast cancer.
@en
A new endpoint for the assessm ...... n with operable breast cancer.
@nl
type
label
A new endpoint for the assessm ...... n with operable breast cancer.
@en
A new endpoint for the assessm ...... n with operable breast cancer.
@nl
prefLabel
A new endpoint for the assessm ...... n with operable breast cancer.
@en
A new endpoint for the assessm ...... n with operable breast cancer.
@nl
P1476
A new endpoint for the assessm ...... n with operable breast cancer.
@en
P2093
A Goldhirsch
R D Gelber
P304
P356
10.1200/JCO.1986.4.12.1772
P407
P577
1986-12-01T00:00:00Z